This study examined the pharmacokinetics and safety of nevirapine for use in the early neonatal period. The authors found that nevirapine at the dose studied was confirmed to be safe, and that the data support nevirapine as a component of presumptive HIV treatment in high-risk neonates.
Citation: Ruel TD, Capparelli EV, Tierney C, Nelson BS, Coletti A, Bryson Y, et al. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV. 2021 Mar;8(3):e149-e157.
Original Article (subscription may be required)